11C 和 18F 标记的胆碱正电子发射计算机断层显像在肿瘤中的临床应用 _West China Medical Journal

Authors：

沈国华 ,  贾志云

四川大学华西医院核医学科（成都 610041）;

Corresponding author：

贾志云, Email: zhiyunjia@hotmail.com

Keywords：

¹¹C-胆碱; ¹⁸F-胆碱; 肿瘤; 正电子发射计算机断层显像

DOI：

10.7507/1002-0179.201603191

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

¹⁸F-氟代脱氧葡萄糖（¹⁸F-fluorodeoxyglucose，¹⁸F-FDG）是目前正电子药物中临床应用最广泛的显像剂，但其在前列腺癌、脑肿瘤、肝癌、肺癌等方面的应用存在一定的局限性。胆碱作为磷脂的前体，是合成细胞膜的必需成分。肿瘤细胞迅速增殖，细胞膜生物合成活动增加，胆碱激酶活性增强，胆碱摄取量增加，这是 ¹¹C 或 ¹⁸F 标记的胆碱可以作为正电子发射计算机断层显像（positron emission tomography/computed tomography，PET/CT）显像剂的基本原理。在临床应用中，胆碱 PET/CT 能大大弥补 ¹⁸F-FDG PET/CT 在某些肿瘤应用中的不足，提高诊断肿瘤的准确性。该文旨在总结 ¹¹C/¹⁸F-胆碱 PET/CT 在肿瘤诊断中的价值。

Citation： 沈国华, 贾志云. ¹¹C 和 ¹⁸F 标记的胆碱正电子发射计算机断层显像在肿瘤中的临床应用 . West China Medical Journal, 2017, 32(10): 1611-1614. doi: 10.7507/1002-0179.201603191 Copy

1.	Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med, 1998, 39(6): 990-995.
2.	Degrado TR, Coleman RE, Wang SY, et al. Synthesis and evaluation of F-18-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res, 2001, 61(1): 110-117.
3.	Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology, 2005, 235(2): 623-628.
4.	Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase <sup>18</sup>F-fluorocholine PET. J Nucl Med, 2006, 47(2): 262-269.
5.	Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with <sup>18</sup>fluorine fluorocholine positron emission tomography. J Urol, 2005, 173(1): 252-255.
6.	Häcker A, Jeschke S, Leeb K, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F] fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol, 2006, 176(5): 2014-2018.
7.	Husarik DB, Miralbell R, Dubs M, et al. Evaluation of F-18-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging, 2008, 35(2): 253-263.
8.	Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol, 2013, 63(6): 1040-1048.
9.	Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5 ng/mL?. Mol Imaging Biol, 2006, 8(1): 43-48.
10.	Cimitan M, Bortolus R, Morassut S, et al. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging, 2006, 33(12): 1387-1398.
11.	Pelosi E, Arena V, Skanjeti A, et al. Role of whole-body F18-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med, 2008, 113(6): 895-904.
12.	Hara T. 11C-choline and 2-deoxy-2-[18F] fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol, 2002, 4(4): 267-273.
13.	Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced Mr imaging. Eur J Nucl Med, 2001, 28(11): 1664-1670.
14.	Tian M, Zhang H, Oriuchi N, et al. Comparison of C-11-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging, 2004, 31(8): 1064-1072.
15.	Tian M, Zhang H, Higuchi T, et al. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography. Mol Imaging Biol, 2004, 6(3): 172-179.
16.	Kwee SA, Ko JP, Jiang CS, et al. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology, 2007, 244(2): 557-565.
17.	Utriainen M, Komu M, Vuorinen V, et al. Evaluation of brain tumor metabolism with [11C] choline PET and 1H-MRS. J Neurooncol, 2003, 62(3): 329-338.
18.	Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using <sup>11</sup>C-choline PET: comparison with 18F-FDG PET. J Nucl Med, 2008, 49(8): 1245-1248.
19.	Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F] fluorocholine: preliminary comparison with [(18)F] FDG PET/CT. Eur J Nucl Med Mol Imaging, 2006, 33(11): 1285-1289.
20.	Wu HB, Wang QS, Li BY, et al. F-18 FDG in conjunction with C-11-Choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med, 2011, 36(12): 1092-1097.
21.	Hara T, Inagaki K, Kosaka N, et al. Sensitive detection of mediastinal lymph node metastasis of lung cancer with <sup>11</sup>C-choline PET. J Nucl Med, 2000, 41(9): 1507-1513.
22.	Khan N, Oriuchi N, Zhang H, et al. A comparative study of C-11-choline PET and F-18-fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun, 2003, 24(4): 359-366.
23.	Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11) C -choline and (18) F -FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med, 2002, 43(2): 167-172.
24.	Hara T, Kosaka N, Suzuki T, et al. Uptake rates of <sup>18</sup>F-fluorodeoxyglucose and <sup>11</sup>C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest, 2003, 124(3): 893-901.
25.	Balogova S, Huchet V, Kerrou K, et al. Detection of bronchioloalveolar cancer by means of PET/CT and F-18-fluorocholine, and comparison with F-18-fluorodeoxyglucose. Nucl Med Commun, 2010, 31(5): 389-397.
26.	Peng Z, Liu Q, Li M, et al. Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer. Clin Lung Cancer, 2012, 13(4): 312-320.

1. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med, 1998, 39(6): 990-995.
2. Degrado TR, Coleman RE, Wang SY, et al. Synthesis and evaluation of F-18-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res, 2001, 61(1): 110-117.
3. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology, 2005, 235(2): 623-628.
4. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med, 2006, 47(2): 262-269.
5. Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol, 2005, 173(1): 252-255.
6. Häcker A, Jeschke S, Leeb K, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F] fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol, 2006, 176(5): 2014-2018.
7. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of F-18-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging, 2008, 35(2): 253-263.
8. Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol, 2013, 63(6): 1040-1048.
9. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5 ng/mL?. Mol Imaging Biol, 2006, 8(1): 43-48.
10. Cimitan M, Bortolus R, Morassut S, et al. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging, 2006, 33(12): 1387-1398.
11. Pelosi E, Arena V, Skanjeti A, et al. Role of whole-body F18-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med, 2008, 113(6): 895-904.
12. Hara T. 11C-choline and 2-deoxy-2-[18F] fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol, 2002, 4(4): 267-273.
13. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced Mr imaging. Eur J Nucl Med, 2001, 28(11): 1664-1670.
14. Tian M, Zhang H, Oriuchi N, et al. Comparison of C-11-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging, 2004, 31(8): 1064-1072.
15. Tian M, Zhang H, Higuchi T, et al. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography. Mol Imaging Biol, 2004, 6(3): 172-179.
16. Kwee SA, Ko JP, Jiang CS, et al. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology, 2007, 244(2): 557-565.
17. Utriainen M, Komu M, Vuorinen V, et al. Evaluation of brain tumor metabolism with [11C] choline PET and 1H-MRS. J Neurooncol, 2003, 62(3): 329-338.
18. Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med, 2008, 49(8): 1245-1248.
19. Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F] fluorocholine: preliminary comparison with [(18)F] FDG PET/CT. Eur J Nucl Med Mol Imaging, 2006, 33(11): 1285-1289.
20. Wu HB, Wang QS, Li BY, et al. F-18 FDG in conjunction with C-11-Choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med, 2011, 36(12): 1092-1097.
21. Hara T, Inagaki K, Kosaka N, et al. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med, 2000, 41(9): 1507-1513.
22. Khan N, Oriuchi N, Zhang H, et al. A comparative study of C-11-choline PET and F-18-fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun, 2003, 24(4): 359-366.
23. Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11) C -choline and (18) F -FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med, 2002, 43(2): 167-172.
24. Hara T, Kosaka N, Suzuki T, et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest, 2003, 124(3): 893-901.
25. Balogova S, Huchet V, Kerrou K, et al. Detection of bronchioloalveolar cancer by means of PET/CT and F-18-fluorocholine, and comparison with F-18-fluorodeoxyglucose. Nucl Med Commun, 2010, 31(5): 389-397.
26. Peng Z, Liu Q, Li M, et al. Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer. Clin Lung Cancer, 2012, 13(4): 312-320.

Previous Article
脾脏病变CT/MRI诊断进展
Next Article
抗血管内皮生长因子时代糖尿病视网膜病变的治疗演变

West China Medical Journal

¹¹C 和 ¹⁸F 标记的胆碱正电子发射计算机断层显像在肿瘤中的临床应用

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content